Elevated UGT2B11 expression during the treatment of prostate cancer with cisplatin-based drugs may indicate that the body has developed resistance to these drugs and that androgen deprivation therapy or immunotherapy may be used to treat the prostate cancer (81, 82). The gene discussed is UGT2B11; the disease is prostate cancer.